FUSION PHARMACEUTICALS INC (FUSN) Stock News

NASDAQ:FUSN - CA36118A1003 - Common Stock

21.55 USD

+0.03 (+0.14%)

Last: 6/3/2024, 8:16:08 PM

21.65 USD

+0.1 (+0.46%)

After Hours: 6/3/2024, 8:16:08 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

FUSN Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Fusion Pharmaceuticals

Acquisition of Fusion Pharmaceuticals Completed

a year ago - By: Fusion Pharmaceuticals

Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement

a year ago - By: Benzinga - Mentions: ELV AZN BSX

Top 4 Health Care Stocks That May Plunge This Month

a year ago - By: BusinessInsider

News Image

FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023

a year ago - By: Benzinga

Recap: Fusion Pharmaceuticals Q4 Earnings

a year ago - By: Fusion Pharmaceuticals

Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca

a year ago - By: Fusion Pharmaceuticals

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

a year ago - By: Kahn Swick & Foti, LLC

FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN

a year ago - By: InvestorPlace

FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q1 2024

a year ago - By: Fusion Pharmaceuticals

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates

a year ago - By: Fusion Pharmaceuticals

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order

a year ago - By: Investor's Business Daily - Mentions: NVS LLY BMY AZN ...

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

a year ago - By: Fusion Pharmaceuticals

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024

a year ago - By: Brodsky & Smith LLC - Mentions: ADTH AGTI LABP ABBV ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)

a year ago - By: Brodsky & Smith LLC - Mentions: AGTI LABP KNTE ABBV ...

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)

a year ago - By: InvestorPlace

FUSN Stock Earnings: Fusion Pharmaceuticals Misses EPS for Q4 2023

a year ago - By: Fusion Pharmaceuticals

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates

a year ago - By: Kahn Swick & Foti, LLC

FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN